Similar Search Results

Narrow search

Spending on new drug development

Adams, Christopher P.; Brantner, Van Vu - In: Health economics 19 (2010) 2, pp. 130-141

Persistent link: https://www.econbiz.de/10008650591

Reconsidering Japan's underperformance in pharmaceuticals : evidence from Japan's anticancer drug sector

Umemura, Maki - In: Enterprise & society : the international journal of … 11 (2010) 3, pp. 560-593

Persistent link: https://www.econbiz.de/10008653171

The future of drug discovery and development : shifting emphasis towards personalized medicine

Amir-Aslani, Arsia; Mangematin, Vincent - In: Technological forecasting & social change : an … 77 (2010) 2, pp. 203-217

Persistent link: https://www.econbiz.de/10003942489

The effects of product liability exemption in the presence of the FDA

Philipson, Tomas J.; Sun, Eric C.; Goldman, Dana P. - 2009

Persistent link: https://www.econbiz.de/10003923781

Pharmaceutical innovation, incremental patenting and compulsory licensing

Velásquez, Germán; Seuba, Xavier - 2011

Persistent link: https://www.econbiz.de/10009546229

Pharmaceutical innovation, incremental patenting and compulsory licensing

Correa, Carlos María - 2011

Despite the decline in the discovery of new chemical entities for pharmaceutical use, there is a significant proliferation of patents on products and processes that cover minor, incremental innovations. A study conducted in five developing countries - Argentina, Brazil, Colombia, India and South...